研究人员开发ACBI3,一种KRAS突变定向药物,为17%至25%的癌症提供更好的治疗。 Researchers develop ACBI3, a KRAS mutation-targeting drug, offering improved treatment for 17-25% of cancers.

邓迪大学和博林格尔·伊安赫尔海姆大学的研究人员研制了ACBI3,一种针对KRAS突变的药物,这种药物在17-25%的癌症中出现。 Researchers at the University of Dundee and Boehringer Ingelheim have developed ACBI3, a drug that targets KRAS mutations, which occur in 17-25% of cancers. ACBI3,即PROTAC,可以消除17个常见的KRAS变种人中的13个,提供比目前方案更有效的治疗方法。 ACBI3, a PROTAC, can eliminate 13 of the 17 common KRAS mutants, offering a more effective treatment approach than current options. 该化合物将通过博林格格海姆的opnMe门户免费提供,以促进对这一关键癌症点的进一步研究. The compound will be available for free through Boehringer Ingelheim's opnMe portal to facilitate further research on this critical cancer target.

文章

Science Daily

News Medical

Medical Xpress

-- 显示更少 --

延伸阅读

相关故事